LOS ANGELES, June 22, 2016 -- Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis, is proud to announce that Vertex Pharmaceuticals Incorporated has awarded the foundation with a grant to support their Extended Hospital Stay Fund.
The Claire's Place Foundation Extended Hospital Stay Fund is a special cache of funds available to families with children living with cystic fibrosis that are experiencing a hospital stay of at least 14 consecutive days. Extended stays are a financial and emotional stress, often requiring a family to travel to a city far from home to receive care. The grants are paid directly to third parties on the families' behalf to cover basic necessities such as mortgage, rent and utilities so that the parents can focus their energies on being with their child in their great time of need.
"It is quite an honor to be recognized by a global biotechnology company that is making huge strides toward developing medicines for people with cystic fibrosis," said Claire's Place Foundation Executive Director Melissa Nordquist. "We are so grateful not only for their show of confidence and support of our program, but also for their commitment to helping people living with this disease around the world. Vertex is truly a breakthrough company with a big heart."
To learn more about Vertex's cystic fibrosis programs and their science, please visit: www.vrtxallincf.com. And, to assist Claire Place Foundation's mission in helping other children with cystic fibrosis, please visit: www.clairesplacefoundation.org.
About Claire's Place Foundation, Inc.
Claire's Place Foundation, Inc. is a 501c3 non-profit organization providing support to children and families affected by cystic fibrosis (CF). Claire's Place Foundation is named in honor of Claire Wineland, now a teenager, who has been living with CF her entire life. The foundation provides grants to families affected by CF, offering both emotional and financial support. A young author of bestseller "Every Breath I Take, Surviving and Thriving with Cystic Fibrosis," Claire's unique inspirational model for people living with this disease has led her to be a TEDx Speaker and receive multiple awards including Seventeen Magazine's "17 Power Teens" of 2016, Fox Teen Choice Awards 2015, Gloria Barron Prize for Young Heroes, Southbay Magazine's "Top 10 South Bay Teen", Looking Beyond LA's "Soaring Spirit Award," and winner of Los Angeles Business Journal's "Small Nonprofit of the Year." She has been featured on Inside Edition, The Dr. Oz Show, CNN, Huffington Post, ABC News, Cosmopolitan, People, Ladies' Home Journal and more. Claire's Place Foundation is a way for Claire to give back with hope, strength, and joy and make meaning of what she has had to go through. For more information and make a donation, please visit www.clairesplacefoundation.org.
About Vertex
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For six years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.
CONTACT: Carrie Callahan
[email protected]


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Italy Fines Apple €98.6 Million Over App Store Dominance
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 



